Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Medchemcomm. 2014 Nov 28;6(3):444–454. doi: 10.1039/C4MD00412D

Table 2.

Inhibitory activities of compounds 9a-9h against tumor cell growth

Compd. R1 GI50 (μM) a
A549 b DU145 KB KBvin
9a graphic file with name nihms647122t7.jpg 37.82 ± 4.88 > 10 c > 10 > 10
9b graphic file with name nihms647122t8.jpg 7.25 ± 0.96 12.62 ± 0.70 15.10 ± 1.16 11.35 ± 2.08
9c graphic file with name nihms647122t9.jpg > 10 > 10 > 10 > 10
9d graphic file with name nihms647122t10.jpg 1.65 ± 0.67 4.33 ± 2.39 5.28 ± 3.49 4.57 ± 2.58
9e graphic file with name nihms647122t11.jpg 10.29 ± 1.98 26.38 ± 4.57 23.55 ± 3.92 20.10 ± 2.95
9f graphic file with name nihms647122t12.jpg 1.33 ± 0.10 1.15 ± 0.33 1.70 ± 0.80 11.93 ± 1.92
9g graphic file with name nihms647122t13.jpg 1.18 ± 0.13 1.21 ± 0.08 1.26 ± 0.05 1.81 ± 0.60
9h graphic file with name nihms647122t14.jpg 2.05 ± 0.52 4.46 ± 0.70 6.25 ± 1.38 3.94 ± 1.04
FVP - 0.14 ± 0.007 0.15 ± 0.007 0.16 ± 0.007 0.18 ± 0.005
a

The GI50 values are the average of three independent measurements.

b

Cell lines: A549 (lung cancer), DU-145 (prostate cancer), KB (nasopharyngeal carcinoma) and KBvin (vincristine-resistant KB subline);.

c

No significant inhibition against tumor cell growth was observed under the concentration of 10 μM.